To accomplish this, we tested the therapeutic potential of Tocilizumab, an IL-6 receptor (IL-6R) blocker that inhibits IL-6 signaling implicated in both burn and cancer-induced WAT browning3,6,13. Here, IL6R is linked to cancer.